Clinical Trial Detail

NCT ID NCT03722407
Title Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

chronic myelomonocytic leukemia

Therapies

Ruxolitinib

Age Groups: adult senior

No variant requirements are available.